Supernus Pharmaceuticals
SUPN
224 hedge funds and large institutions have $1.4B invested in Supernus Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 76 increasing their positions, 74 reducing their positions, and 34 closing their positions.
266% more call options, than puts
Call options by funds: $3.33M | Put options by funds: $911K
6% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 34
5% more capital invested
Capital invested by funds: $1.33B → $1.4B (+$65.1M)
3% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 74
0.36% more ownership
Funds ownership: 100.46% → 100.82% (+0.36%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less funds holding
Funds holding: 225 → 224 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$21.5M |
| 2 |
TCM
Tributary Capital Management
Omaha,
Nebraska
|
+$8.82M |
| 3 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
+$8.25M |
| 4 |
AC
Armistice Capital
New York
|
+$8.17M |
| 5 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$7.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$27.5M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$17.2M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$11.8M |
| 4 |
Man Group
London,
United Kingdom
|
-$5.36M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.62M |
SUPN Hedge Fund Activity: Q1 2021 in Review
224 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2021, worth a combined $1.4B — up 4.9% from $1.33B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new SUPN positions and 34 closed out — a net gain of 2 holders — while 76 added to existing stakes and 74 trimmed.
The largest buyer was Frontier Capital Management, opening a new position worth an estimated $21.5M. The largest seller was Fuller & Thaler Asset Management, cutting an estimated $27.5M.
- 224 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2021, down from 225 in Q4 2020.
- Funds reported $1.4B of Supernus Pharmaceuticals stock for Q1 2021, up 4.9% quarter-over-quarter.
- 36 funds opened new Supernus Pharmaceuticals positions in Q1 2021 and 34 closed out, a net change of +2 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2021 was Frontier Capital Management, an estimated $21.5M added.
- The largest Supernus Pharmaceuticals seller in Q1 2021 was Fuller & Thaler Asset Management, an estimated $27.5M sold.
Based on aggregated 13F filings for Q1 2021.